Want to see BMEA full AI Analyst Report?
BMEA Stock Chart & Stats
$2.21
$0.07(1.75%)
At close: 4:00 PM EST
$2.21
$0.07(1.75%)
Day’s Range― - ―
52-Week Range$0.87 - $2.99
Previous CloseN/A
Volume309.16K
Average Volume (3M)2.40M
Market Cap
$94.71M
Enterprise Value$27.94M
Total Cash (Recent Filing)$44.69M
Total Debt (Recent Filing)$1.24M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Aug 03, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding72,299,440
10 Day Avg. Volume5,869,688
30 Day Avg. Volume2,395,415
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-0.92
Enterprise Value/Market Cap0.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-47.12
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$7.20Price Target Upside225.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Covalent PlatformA proprietary covalent discovery platform gives durable scientific differentiation, enabling the company to design selective, long‑acting small molecules across oncology and metabolic indications. Platform-driven pipelines can generate multiple value‑creating programs and attract partners over time.
Positive Phase 2 T1D DataRobust, durable 52‑week efficacy and clean safety in Phase 2 materially de‑risks icovamenib's biology and supports broader clinical development. Demonstrated differentiation versus immune suppression can expand the target patient window and improve partnering and regulatory prospects.
Improving Cash Burn TrendsMeaningful reduction in operating cash outflow signals better cost discipline and extends runway versus prior periods. Coupled with modest leverage, improved cash dynamics reduce short‑term solvency pressure and increase optionality for executing additional trials or partnerships.
Bears Say
No Commercial RevenueAbsent product revenue, the company relies on external financing or deals to fund operations. Continued operating losses translate into real cash burn, making long‑term sustainability contingent on successful trials, partnerships, or dilutive financings rather than organic cash generation.
Eroded Equity BaseA sharp decline in equity and total assets materially reduces the company's financial cushion. That erosion increases likelihood of future dilution, limits strategic flexibility, and raises execution risk if clinical timelines slip or unexpected costs arise requiring rapid capital raises.
Shareholder Dissent / Governance RiskSignificant shareholder rejection of director nominees signals governance friction and investor dissatisfaction. Persistent governance issues can hinder board stability, complicate strategic decisions, and deter potential partners or investors during critical financing or collaboration negotiations.
Biomea Fusion News
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $0.87 and its highest was $2.99 in the past 12 months.
What is Biomea Fusion’s market cap?
Biomea Fusion’s market cap is $94.71M.
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Aug 03, 2026 which is in 23 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on May 06, 2026. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.231 by $0.061.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -0.22.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 72,299,440 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.231. Following the earnings report the stock price went up 1.875%.
Which hedge fund is a major shareholder of Biomea Fusion?
Currently, no hedge funds are holding shares in BMEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biomea Fusion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.20 (225.79% Upside)
$7.20 (225.79% Upside)
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.77%
12-Months-Change
Fundamentals
Return on Equity
-196.72%
Trailing 12-Months
Asset Growth
-15.75%
Trailing 12-Months
Company Description
Biomea Fusion
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.
BMEA Stock 12 Month Forecast
Average Price Target
$7.20
▲(225.79% Upside)
Technical Analysis
Ownership Overview
8.66% Insiders
11.22% Mutual Funds
<0.01% Other Institutional Investors
75.99% Public Companies and
Individual Investors